



The patient → Doctors → LVL Médical → The patient



Financial Update of 26/10/2009

LVL MEDICAL GROUP

CONSOLIDATED 2008-2009 REVENUES: + 18.9%

AN ACCELERATING GROWTH TREND !

Consolidated revenues for the year amounted to €136,151m in total as at 30/09/2009, compared with €114,533m as at 30/09/2008, i.e. a growth rate of 18.9%.

On a like-for-like basis, revenues for the financial year would have amounted to €124,475m, i.e. an increase of 9.9%.

→ FRANCE

Revenues amounted to €86,122m as at 30/09/2009, up 9.4% on a like-for-like basis compared to the previous year.

This accelerating growth trend is due to sustained growth in the Group's strategic businesses, especially Perfusion, Nutrition and Insulin Therapy (PNIT) where LVL Médical consolidated its market position and achieved annual revenues of €30,807m as at 30/09/2009, i.e. an aggregate annual growth rate of 16.3% compared with the previous financial year.

The respiratory assistance activities saw slightly lower growth, with revenues amounting to €55,315m as at 30/09/2009, i.e. an increase of 5.9% compared with the previous financial year.

→ GERMANY

Revenues of the home-based nursing care businesses saw a sharp increase, amounting to €49,621m as at 30/09/2009, compared with €34,493m as at 30/09/2008, i.e. a growth rate of 43.9%.

On a like-for-like basis, the growth rate of these businesses would have been 11.2%.

→ EQUITY AND STRATEGIC PARTNERSHIP

Malakoff Médéric, one of France's leading health and personal insurance groups, has committed to acquire a 13.2% interest in the equity capital of LVL Médical Group from Amber Master Fund, at a price of €14.00 per share. Within this framework, the Malakoff Médéric Group and the members of the Lavorel Family, who are LVL Médical Group's controlling shareholders, have reached a shareholders' agreement for a period of five years during which they have stated their intention to act in concert. The agreement also includes an ambitious strategic partnership, which is favourable to the Group's business activities in the longer-term.

→ OUTLOOK

In light of the points detailed above and of investments that are beginning to bear fruit in terms of growth and organisation, the Group can confidently announce that the underlying and profitable growth trend will continue in the current financial year.

→ NEXT UPDATE

LVL Medical will publish its annual results for the year ending September 30th 2009 on December 14th 2009 after the Stock Exchange close.

Founded in 1989, the LVL Médical Group has grown, over the years, into a leading provider in different areas of medical intervention such as respiratory assistance, perfusion, nutrition and insulin therapy and home-care services in France. LVL Médical takes care of over 40,000 patients in France every day. Over 10,000 specialist practitioners trust the LVL Médical Group to monitor their patients.

In Germany, the Group is a leading provider of home nursing care services, and of intensive care services, both in the home and in purpose-built units, through its Bonitas subsidiary. A top-ranking player in the care of patients suffering from illnesses that require increasingly complex treatment, over the years, LVL has become a real partner for the authorities with whom it negotiates patient care agreements directly.

The Group currently employs over 2,000 people.

LVL Médical Group Communication Department

Phone +33 (0)4 26 68 68 68
actionnaires@
lvl-medical.fr

Euronext
Compartment C Paris
ISIN FR0000054686
Reuters LVL.M.PA
Bloomberg LVL
Indices :
SBF 250
CAC Small 90

LVL
LISTED
NYSE
EURONEXT



lvl-medical.com